Skip to main content

Dr. Patrick Grierson, MD

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
12
In the NPI registry since
2014
Medicare patients seen, 2024
250

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2014Medical school: Ohio State University College of Medicine
  • 2014Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    MO license 2017020379
  • Internal Medicine Physician
    MO license 2017020379

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
250
Services billed
27,594
Patients’ average age
72
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, oxaliplatin, 0.5 mg8,90012
Injection, fosaprepitant, 1 mg7,20023
Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram6,42011
Injection, pembrolizumab, 1 mg4,60012
Injection, dexamethasone sodium phosphate, 1 mg1,29063
Injection, palonosetron hcl, 25 mcg93046
Injection, leucovorin calcium, per 50 mg65624
Injection, fluorouracil, 500 mg51226
Injection, granisetron hydrochloride, 100 mcg46028
Injection of additional new drug or substance into vein23875

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 2 companies reported 2 payments worth $137 in total to this clinician.

By company
Exelixis Inc.$121
Taiho Oncology, Inc.$15.77
By type
Food and Beverage$137

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Missouri →

Industry-funded research

Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $1,397,776 in research payments for these studies, mostly to the institutions running them.

  • A phase 1B2 dose escalation and expansion study of tucatinib in combination with trastuzumab and oxaliplatinbased chemotherapy or pembrolizumabcontaining combinations for HER2 gastrointestinal cancers
    Pfizer Inc.
  • An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor activity of N0112 in Human Leukocyte Antigen-C0802-Positive Adult Subjects with Unresectable, Advanced, and/or Metastatic Sol…
    AstraZeneca Pharmaceuticals LP
  • A study of KK2269 in adult participants with solid tumors
    Kyowa Kirin Co., Ltd
  • A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care gemcitabine, cisplatin, and durvalumab for first line locally advanced or metastatic HER2-expressing Biliary Tract Cancer
    AstraZeneca Pharmaceuticals LP
  • A modular Phase I II Open label Dose Escalation and Dose Expansion Study to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Efficacy of AZD9793 a T cell engaging Antibody Targeting Glypican3 GPC3 in Adult Pa…
    AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Saint Louis

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 17, 2025), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1720492192. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.